Trials involving Multiple Types of Cancer

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Merck) MK-3475-587 / KEYNOTE 587A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab TrialMcWhirter, Dr ElaineRecruitment on hold - COVID-19NCT03486873
(UHN) OCTANEOntario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE)Hotte, Dr SebastienRecruitment on hold - COVID-19NCT02906943
(CCTG) IND.238A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related ToxicityEllis, Dr PeterRecruitment on hold - COVID-19NCT03847649
(HHS) CRUSSHStereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trialSchnarr, Dr KaraRecruitment on hold - COVID-19NCT03529708
(IMV) Immunovac / P1719-SUR-Z11A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid TumoursHirte, Dr HalRecruitment on hold - COVID-19NCT03836352
(BMS) CA021002A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid TumorsHotte, Dr SebastienRecruitment on hold - COVID-19NCT03251924
(Tesaro) 4010-01-001 / GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1
Monoclonal Antibody, in Patients with Advanced Solid Tumors
Elit, Dr LaurieRecruitment on hold - COVID-19NCT02715284
(Ayala) AL-ACC-01 / ACCURACYA Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch MutationsHotte, Dr SebastienRecruitment on hold - COVID-19NCT03691207
(Roche) BP29842AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY,
PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE CONSISTING OF INTERLEUKIN 2 VARIANT (IL-2v) TARGETING FIBROBLAST ACTIVATION PROTEIN- (FAP), AS A SINGLE AGENT (PART A) OR IN COMBINATION WITH TRASTUZUMAB OR CETUXIMAB (PART B OR C)
Hotte, Dr SebastienRecruitment on hold - COVID-19NCT02627274
Download PDF